Umabs DB作为目前全球最全面的抗体药物专业数据库,收录全球近10000个从临床前到商业化阶段抗体药物,涉及靶点1600+,涉及疾病种类2400+,研发机构2900+,覆盖药物蛋白序列、专利和临床等多种专业信息。Umabs DB药物数据库已正式开放上线,可访问www.umabs.com注册享受7天免费试用。
2025年3月25日,2025 AACR摘要公布,信达生物公布了两款ADC药物。其中IBI3014为靶向TROP-2/PD-L1双抗ADC,IBI3010为双表位的FR ADC药物。
同时基于PD-1/IL-2药物IBI363的初步成功开发,信达又推出了一款PD-1/IL12药物IBI3026,以及一款EGFR/CDH17/CD16A三抗药物IBI3019。
344 / 11 - IBI3014, a TROP2xPD-L1 bi-specific ADC integrating ADC killing with checkpoint blockade within one molecule, exhibits promising efficacy and safety in preclinical models
Antibody-drug conjugates (ADCs) have emerged as a distinguished class of anticancer therapeutics. ADCs targeting Trophoblast Cell Surface Antigen 2 (TROP2) have shown efficacy in treating various epithelial tumors, such as non-small cell lung cancer (NSCLC) and triple-negative breast cancer (TNBC). Programmed Death Ligand 1 (PD-L1) serves as both an immune checkpoint and a tumor-associated antigen (TAA), commonly overexpressed in diverse tumor types. Growing evidence showed that ADCs can increase the efficacy of immunotherapeutic agents by multiple mechanisms, such as induction of immunogenic cell death, dendritic cell maturation, increase of T cell infiltration and expression of immune-regulatory proteins including PD-L1 and MHC. Both preclinical and early clinical studies suggest that ADCs and immunotherapy are promising combination options for tumor treatment. IBI3014 is an innovative TROP2 and PD-L1 dual-targeting ADC, comprising a humanized bispecific antibody linked to a novel DNA topoisomerase I inhibitor, NT1, via a cleavable linker. In vitro studies demonstrated the unconjugated bispecific antibody of IBI3014 has potent internalization activity potent immune checkpoint blocking activity. IBI3014 demonstrated superior cytotoxicity to benchmark and parental ADCs across several cell line-derived xenograft (CDX) models with different TROP2 and PD-L1 expression pattern, offering broader tumor type coverage. IBI3014 showed acceptable stability profile in mice and monkeys and can be well tolerated in monkeys with a highest non-severely toxic dose (HNSTD) of 50 mg/kg. Conclusion: IBI3014 represents a first-in-class bispecific ADC that integrates targeted cytotoxicity with checkpoint blockade within a single molecule. This dual mechanism of action not only enhances therapeutic efficacy but also maintains a favorable safety profile, which provides a promising approach for cancer therapy.LB222 / 19 - Preclinical characterization of IBI3010, a FRα targeting biparatopic antibody-drug conjugate (ADC), for the treatment of FRα expressing tumors
IBI3026, a first-in-class anti-PD-1/IL-12 fusion protein, demonstrates the potential to be a new immuno-oncology therapy by releasing the break in immune response and strongly activating T and NK cells in the tumor microenvironment
IBI3019, a first-in-class EGFR/CDH17/CD16A tri-specific antibody, demonstrated potent efficacy against CRC and an excellent safety profile in preclinical studies
更多有关抗体药物具体信息、专利及临床等动态进展,敬请关注Umabs DB全球数据库(www.umabs.com)的更新。
拓展阅读:
第3项三期:百利天恒启动HER2 ADC乳腺癌新辅助联合疗法临床
CDH17:康诺亚申请第二款ADC药物
德琪医药:ADC和TCE双向驱动
溢价37.2%:阿斯利康认购9.15%和铂股权
平常心之双抗合集
HER3/c-Met:恒瑞公开首个双抗ADC
ORR的执念
再鼎启动DLL-3 ADC二期临床
Elevation终止CLND18.2 ADC的研发
皮下PD-1:K药仍是最佳,ADA仅为1.4%
Dato-DXd+奥西替尼联用数据公布,凸显科伦博泰的同类最佳
审美疲劳之ADC合集
非小细胞肺癌:石药启动EGFR ADC首个三期临床
阿斯利康更新B7H4 ADC临床数据,即将进入三期临床
扩展前线:恒瑞启动Nectin-4 ADC在膀胱癌第2项三期临床
阿斯利康头铁:7.5亿美元引进Alteogen透明质酸酶技术,后者深陷侵权风险
SGBCC 2025:恒瑞HER2 ADC更新一期临床数据
Chugai推出第二款CD3/4-1BB三抗
多箭齐发:宜联B7H3 ADC欲全覆盖小细胞肺癌
康方递交第二款ADC药物IND申请
Sutro战略重组:all in ADC
柳叶刀评论文章:依沃西一线肺癌PFS是否已经足够?
刘勇军谈自免:迭代创新
辉瑞启动全球首个CD25 ADC临床试验,第一三共和AZ均有布局
头颈鳞癌:石药启动Nectin-4 ADC+EGFR+PD-1三联联合疗法
再挑战K药:阿斯利康启动PD-1/TIGIT双抗肺癌第二项头对头临床试验
全球首个OX40单抗上市有望:安进Rocatinlimab再取得两项三期临床成功
科伦博泰:全球首款获批肺癌的TROP-2 ADC
前列腺癌:默沙东连续启动B7-H3 ADC第4项临床试验
CytomX放弃屏蔽肽EGFR/CD3双抗的开发
ALX大涨30%:CD47还有救命稻草?
应对专利悬崖:K药皮下制剂也被专利绊了一跤
CDH17:宜联ADC平台的第11款药物进入临床
3501例:Amgen启动重磅GLP-1偶联蛋白首个三期临床
散则满天星:前普方CMO参与创办新锐ADC公司Callio
二期临床P值0.0501,如何展望三期?
尿路上皮癌:百利天恒启动EGFR/HER3双抗ADC第9项三期临床试验
十年一箭:菲鹏制药申报PD-1/IL-10融合蛋白临床试验申请
博锐生物双表位ROR1 ADC获批临床
卵巢癌:翰森启动全球首个B7H4 ADC三期临床
Enhertu:首个胃癌三期临床取得成功
Sanofi将ILT2抗体退回Biond
毒素偶联物:给CD47抗体插上翅膀
第一三共:2026年Enhertu销售额或翻倍
辉瑞拉胯:肿瘤研发日沦为ADC过场
关于Umabs DB
Umabs DB是目前全球最全面的抗体药物专业数据库,收录全球近10000个从临床前到商业化阶段抗体药物,涉及靶点1600+,涉及疾病种类2400+,研发机构2900+,覆盖药物蛋白序列、专利和临床等多种专业信息。Umabs DB药物数据库已正式开放上线,可访问www.umabs.com注册享受7天免费试用,更多信息可联系info@umabs.com